BOOKS BY CATEGORY
Your Account
An Introduction to Pharmacovigilance
This book is currently unavailable – please contact us for further information.
Price
Quantity
€32.93
(To see other currencies, click on price)
Paperback / softback
Add to basket  

MORE ABOUT THIS BOOK

Main description:

Pharmacovigilance is the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug–related problems.

This introductory guide is designed to aid the rapid understanding of the key principles of pharmacovigilance. Packed full of examples illustrating drug safety issues it not only covers the processes involved, but the regulatory aspects and ethical and societal considerations of pharmacovigilance.


Covering the basics step–by–step, this book is perfect for beginners and is essential reading for those new to drug safety departments and pharmaceutical medicine students.


Back cover:

Pharmacovigilance is the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug–related problems.

This introductory guide is designed to aid the rapid understanding of the key principles of pharmacovigilance. Packed full of examples illustrating drug safety issues it not only covers the processes involved, but the regulatory aspects and ethical and societal considerations of pharmacovigilance.


Covering the basics step–by–step, this book is perfect for beginners and is essential reading for those new to drug safety departments and pharmaceutical medicine students.


Contents:

Acknowledgements ix


Foreword x


Preface xii

Chapter 1 What is pharmacovigilance and how has it developed? 1


Origins and definition of pharmacovigilance 1


Scope and purposes of pharmacovigilance 3


Development of pharmacovigilance since the 1960s 5


Conclusion 14


Chapter 2 Basic concepts 15


Introduction 15


Adverse drug reactions 15


The concept of safety 21


Causation was the drug responsible? 25


Conclusion 29


Chapter 3 Types and sources of data 30


Introduction 30


Pre–clinical studies 30


Human volunteer studies 31


Clinical trials 31


Post–marketing surveillance 33


Systematic reviews and meta–analysis 42


Conclusion 43


Chapter 4 The process of pharmacovigilance 44


Overview a risk management process 44


Signal detection 44


Evaluation and investigation 50


Taking action 52


Communication 56


Crisis management 59


Conclusion 60


Chapter 5 Regulatory aspects of pharmacovigilance 61


Introduction 61


Legislation and guidelines 62


Regulatory pharmacovigilance systems 64


Obligations of pharmaceutical companies 65


Risk management planning 69


Conclusion 73


Chapter 6 International collaboration 74


Introduction 74


World Health Organisation 75


Council for the Organisation of Medical Sciences 75


International Conference on Harmonisation 78


Conclusion 79


Chapter 7 Ethical and societal considerations 80


Introduction 80


Stakeholders and their perspectives 80


Ethical principles 83


Ethical safeguards in relation to safety 84


Transparency 85


Conflicts of interest 86


Conclusion 87


Chapter 8 Future directions 89


Introduction current limitations 89


Meeting the challenges 90


Conclusion 93


Chapter 9 Learning more about pharmacovigilance 94


Books 94


Journals 95


Useful websites 95


Courses 96


International societies 96


Conclusion 96


Glossary 98


Index 101


PRODUCT DETAILS

ISBN-13: 9781405194716
Publisher: John Wiley & Sons Ltd (Wiley–Blackwell)
Publication date: October, 2009
Pages: 120
Dimensions: 140.00 x 215.00 x 7.48
Weight: 168g
Availability: Not available (reason unspecified)
Subcategories: Diseases and Disorders, Pharmacology

MEET THE AUTHOR

Dr Patrick Waller has been an independent consultant in pharmacovigilance and pharmacoepidemiology based in Southampton since 2002. He also holds honorary academic appointments at the London School of Hygiene and Tropical Medicine and the University of Dundee.  From 1998–2004 he was Visiting Professor in the Department of Pharmacological Sciences at the University of Newcastle–upon–Tyne.  From 1990–2002 he worked in the field of pharmacovigilance for the Medicines Control Agency in London. From 1998–2000 he was one of the UK delegates to the Committee for Proprietary Medicinal Products and Chairman of its Pharmacovigilance Working Party.

CUSTOMER REVIEWS

Average Rating